ILMN - Illumina, Inc.
| Previous close | 282.65 |
| Open | 282.35 |
| Bid | 280.00 x 800 |
| Ask | 283.40 x 800 |
| Day's range | 281.40 - 286.20 |
| 52-week range | 167.98 - 293.15 |
| Volume | 46,970 |
| Avg. volume | 802,876 |
| Market cap | 41.841B |
| Beta | 0.94 |
| PE ratio (TTM) | 73.74 |
| EPS (TTM) | 3.86 |
| Earnings date | 30 Jul 2018 - 3 Aug 2018 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 278.38 |
- Zacks•3 days ago
Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips
Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips
- Motley Fool•3 days ago
Better Buy: Illumina, Inc. vs. Pacific Biosciences of California
Which stock wins in a match-up between these two gene-sequencing leaders?
- Motley Fool•3 days ago
Illumina Might Be Overlooking Its Top Competitor; Here's Why Investors Shouldn't
The fast pace of innovation in biotech is the biggest risk to Illumina's future. With a $42 billion market cap, it could sting sooner than investors think.
- Zacks•4 days ago
Anika Reports Top Line Data from CINGAL Study, Shares Slump
Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.
- Zacks•4 days ago
4 of the Best Efficient Stocks to Buy for Superb Returns
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
- Zacks•5 days ago
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
- Zacks•5 days ago
Alexion (ALXN) Submits Application for ALXN1210 with FDA
Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).
- Zacks•5 days ago
Walgreens Boots' Retail Pharmacy Strong Despite Several Woes
Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.
- Zacks•5 days ago
BSX or BAX: Which is a Better Pick for Your Portfolio Now?
After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).
- Zacks•5 days ago
Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug
Agios Pharmaceuticals, Inc. (AGIO), initiates a phase III ACTIVATE study which will evaluateits lead rare genetic diseases candidate, AG-348 in patients with PK deficiency who do not receive regular blood transfusions.
- Zacks•6 days ago
Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis
Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.
- Zacks•6 days ago
Hologic's New Panther Fusion System Gets Health Canada Nod
Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.
- Zacks•6 days ago
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.
- Zacks•10 days ago
Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone
Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.
- Zacks•11 days ago
Flex Pharma Down on Workforce Reduction, Ends Phase II Study
Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.
- Zacks•11 days ago
Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA
Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.
- Zacks•14 days ago
CVS Health's PBM Selling Season Remains Solid, Retail Grows
CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.
- Motley Fool•17 days ago
Here's Why Illumina, Inc. Stock Gained 13.1% in May
The DNA-sequencing leader continued its slow and steady rise.
- Zacks•18 days ago
Here's Why You Should Invest in Genomic Health (GHDX) Now
Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.
- Zacks•18 days ago
ResMed Reports Positive Results for Bilevel PAP Device Study
Positive results from the Bilevel Rescue study are expected to boost the uptake of ResMed's (RMD) bilevel devices.
- Simply Wall St.•20 days ago
What You Must Know About Illumina Inc’s (NASDAQ:ILMN) Financial Strength
Illumina Inc (NASDAQ:ILMN), a large-cap worth US$41.20B, comes to mind for investors seeking a strong and reliable stock investment. Big corporations are much sought after by risk-averse investors who findRead More...
- Zacks•20 days ago
Amedisys (AMED) Buys Back 2.4M Shares From KKR, Stock Up
Amedisys (AMED) works on its strategy to deploy capital in an accretive manner, maintaining low leverage and substantial borrowing capacity for future investment.
- Zacks•20 days ago
Medtronic's (MDT) CRHF Arm Growth Strong, Rising Costs a Woe
The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.
- Zacks•20 days ago
Bristol-Myers (BMY) Reports Data from CheckMate-214 Study
Bristol-Myers Squibb (BMY) announces encouraging data from the phase III CheckMate -214 study.
